Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Nelarabine Injection, 250 mg/50 mL (5 mg/mL) (Single-Dose Vial). It has enclosed press release.
The above information is a part of company’s filings submitted to BSE.